Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Taro Pharmaceutical Industries Ltd (NYSE:TARO)

128.30
Delayed Data
As of Aug 26
 +1.52 / +1.20%
Today’s Change
122.99
Today|||52-Week Range
157.99
-16.98%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Pharmaceuticals: Generic
MARKET CAP
$5.4B

Company Description

Taro Pharmaceutical Industries Ltd. engages in the development, manufacturing, and marketing of prescription and over-the-counter pharmaceutical products in the U.S., Canada, and Israel. Its products are used for dermatological and topical, cardiovascular, neuropsychiatric, and anti-inflammatory therapeutic categories. It offers semi-solids formulations such as creams and ointments; and other dosage forms including liquids, capsules, and tablets. The company was founded in 1950 and is headquartered in Haifa Bay, Israel.

Contact Information

Taro Pharmaceutical Industries Ltd.
14 Hakitor Street
Haifa Bay Haifa 2624761
P:(724) 847-5700
Investor Relations:

Employees

Shareholders

Mutual fund holders5.91%
Other institutional10.96%
Individual stakeholders10.60%

Top Executives

Kal SundaramChief Executive Officer & Director
Itamar KarsentiVice President & Operations Head-Haifa
Avi AvramoffGlobal Vice President-Research & Development
Stephen ManzanoSecretary, Group Vice President & General Counsel
Mariana BacaluGroup Vice President-Quality Affairs